Arrowhead climbs

Arrowhead climbs after licensing deal with Sarepta
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) for various clinical and preclinical programs.
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High
Shares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 million deal with Sarepta Therapeutics ($SRPT), which saw a 3% uptick. Arrowhead is also expected to report its fourth-quarter earnings after the bell.
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.
Sarepta Inks Global Licensing Deal With Arrowhead, Announces $500 Mln Share Buyback Program
In exchange, Arrowhead will receive an upfront payment of $500 million and an equity investment of $325 million in its common stock. The company will also receive $250 million in annual installments of $50 million over five years, along with milestone payments and royalties.
Arrowhead Pharmaceuticals (ARWR) Soars with Strategic Deal: A Transformative Move for the Company
Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and silence specific genes that are implicated in a variety of diseases, particularly rare and genetic disorders.
FierceBiotech4h
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Yahoo4h
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
STAT19h
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of ...
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
ENDPOINTS NEWS3h
Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks
Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...